Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Ralph, Arlinghaus"'
Publikováno v:
Oncogene. 12/9/2002 Review, Vol. 21 Issue 56, p8535-8535. 1p.
Autor:
Pier Giuseppe Pelicci, Ralph Arlinghaus, Geraldine Mbamalu, Jiaxin Liu, Lorri Puil, Gerald D. Gish, Tony Pawson, David D.L. Bowtell
Publikováno v:
The EMBO Journal. 13:764-773
The cytosolic 185 and 210 kDa Bcr-Abl protein tyrosine kinases play important roles in the development of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (Ph+ ALL). p185 and p210 Bcr-Abl cont
Autor:
Ana M, Tari, Yolanda, Gutiérrez-Puente, Giuseppe, Monaco, Clifton, Stephens, Tong, Sun, Michael, Rosenblum, John, Belmont, Ralph, Arlinghaus, Gabriel, Lopez-Berestein
Publikováno v:
International journal of oncology. 31(5)
We previously demonstrated that liposome-incorporated antisense oligodeoxynucleotide specific for the grb2 mRNA (L-Grb2) inhibited Grb2 protein expression and the proliferation of bcr-abl-positive leukemia cell lines. To determine whether L-Grb2 has
Autor:
Ralph, Arlinghaus, Tong, Sun
Publikováno v:
Cancer treatment and research. 119
Autor:
Nicholas J, Donato, Ji Y, Wu, Jonathan, Stapley, Hui, Lin, Ralph, Arlinghaus, Bharat B, Aggarwal, Shishir, Shishodia, Maher, Albitar, Kimberly, Hayes, Hagop, Kantarjian, Moshe, Talpaz, Shishir, Shishodin
Publikováno v:
Cancer research. 64(2)
Imatinib mesylate (IM) binds to the BCR-ABL protein, inhibiting its kinase activity and effectively controlling diseases driven by this kinase. IM resistance has been associated with kinase mutations or increased BCR-ABL expression. However, disease
Autor:
Hagop M, Kantarjian, Susan, O'Brien, Jorge E, Cortes, Sergio A, Giralt, Mary Beth, Rios, Jianqin, Shan, Francis J, Giles, Deborah A, Thomas, Stefan, Faderl, Marcos, De Lima, Guillermo, Garcia-Manero, Richard, Champlin, Ralph, Arlinghaus, Moshe, Talpaz
Publikováno v:
Blood. 100(5)
Twenty-eight adults with chronic myelogenous leukemia (CML) that had relapsed after allogeneic stem cell transplantation (SCT) received imatinib mesylate (400-1000 mg/d). Disease was in chronic phase in 5 patients, accelerated in 15, and blastic in 8
Autor:
Kantarjian, Hagop M., Moshe Talpaz, Jorge Cortes, Brien, Susan O., Stefan Faderl, Deborah Thomas, Francis Giles, Mary Beth Rios, Jianqin Shan, Ralph Arlinghaus
Publikováno v:
Scopus-Elsevier
Augusta University-Pure
Augusta University-Pure
The purpose of our investigation was to evaluate the response and minimal residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic myeloid leukemia (CML) treated with imatinib mesylate.One hundred eighty patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4939fb7675cd3c67b4b8b5744302e1bc
http://www.scopus.com/inward/record.url?eid=2-s2.0-0346756405&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-0346756405&partnerID=MN8TOARS
Autor:
Singh, Balraj1, Shamsnia, Anna1, Raythatha, Milan R.1, Milligan, Ryan D.1, Cady, Amanda M.1, Madan, Simran1, Lucci, Anthony1 alucci@mdanderson.org
Publikováno v:
PLoS ONE. Oct2014, Vol. 9 Issue 10, p1-14. 14p.
Autor:
Goldman, J. M.1 jgoldman@imperial.ac.uk, Green, A. R.2, Holyoake, T.3, Jamieson, C.4, Mesa, R.5, Mughal, T.6, Pellicano, F.3, Perrotti, D.7, Skoda, R.8, Vannucchi, A. M.9
Publikováno v:
Leukemia (08876924). Oct2009, Vol. 23 Issue 10, p1708-1715. 8p. 1 Chart.
Autor:
Arlinghaus, Ralph1 (AUTHOR) rarlingh@mdanderson.org, Leng, Xiaohong1 (AUTHOR)
Publikováno v:
Leukemia & Lymphoma. Apr2008, Vol. 49 Issue 4, p600-603. 4p. 1 Color Photograph, 1 Diagram.